Evolocumab for Primary Prevention of Cardiovascular Events in Patients without Atherosclerosis
|
Reviewed & Translated by Dat Tien Nguyen, B.A, ScM.
|
Posted on April 15th, 2026
|
Previous studies have established that lowering low-density lipoprotein (LDL) cholesterol reduces the risk of recurrent cardiovascular events in patients with a history of myocardial infarction or stroke. However, the benefit of intensive LDL-lowering therapy in individuals without established atherosclerosis or diabetes remains uncertain. A recent study published in the Journal of the American Medical Association evaluated whether evolocumab could reduce the risk of a first major cardiovascular event in this lower-risk population.
Funding Source(s): Amgen
The trial enrolled 3,655 participants with a median age of 65 years who had no prior history of myocardial infarction or stroke. At baseline, participants had a median LDL cholesterol level of 132 mg/dL and triglyceride levels of approximately 170 mg/dL. Most participants were already receiving lipid-lowering therapy, with 84% on statins and about 14% on ezetimibe. Participants were randomly assigned to receive subcutaneous injections of either placebo or evolocumab at a dose of 140 mg every two weeks. Evolocumab is a monoclonal antibody that inhibits PCSK9, preventing it from binding to LDL receptors. This allows LDL receptors to recycle back to the hepatocyte surface, enhancing clearance of LDL cholesterol from the bloodstream.
After a median follow-up of 4.8 years, evolocumab reduced the risk of major cardiovascular outcomes - including coronary heart disease death, myocardial infarction, and ischemic stroke - by 31% compared with placebo. However, the researchers noted that the onset of clinical benefit was delayed in this population without established atherosclerosis, occurring later than what has been observed in higher-risk patients. These findings suggest that while PCSK9 inhibition can be effective for primary prevention, the timing and magnitude of benefit may differ compared to secondary prevention settings.
Funding Source(s): Amgen
The trial enrolled 3,655 participants with a median age of 65 years who had no prior history of myocardial infarction or stroke. At baseline, participants had a median LDL cholesterol level of 132 mg/dL and triglyceride levels of approximately 170 mg/dL. Most participants were already receiving lipid-lowering therapy, with 84% on statins and about 14% on ezetimibe. Participants were randomly assigned to receive subcutaneous injections of either placebo or evolocumab at a dose of 140 mg every two weeks. Evolocumab is a monoclonal antibody that inhibits PCSK9, preventing it from binding to LDL receptors. This allows LDL receptors to recycle back to the hepatocyte surface, enhancing clearance of LDL cholesterol from the bloodstream.
After a median follow-up of 4.8 years, evolocumab reduced the risk of major cardiovascular outcomes - including coronary heart disease death, myocardial infarction, and ischemic stroke - by 31% compared with placebo. However, the researchers noted that the onset of clinical benefit was delayed in this population without established atherosclerosis, occurring later than what has been observed in higher-risk patients. These findings suggest that while PCSK9 inhibition can be effective for primary prevention, the timing and magnitude of benefit may differ compared to secondary prevention settings.